Compare Adaptive Biotechnologies Corp (ADPT) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Check Point Software Technologies Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Check Point Software Technologies Ltd trades at $136.4 (market cap $14.43B). The key difference: Check Point Software Technologies Ltd is far larger — about 4.3× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Check Point Software Technologies Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | CHKP | |
|---|---|---|
Market Cap | $3.33B | $14.43B |
Sector | Health | Technology |
52-Week High | $22.37 | $231.23 |
52-Week Low | $10.24 | $112.47 |
Enterprise Value | $3.19B | $13.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CHKP trades at $138.87, up 1.68% today, with a bullish technical outlook supported by moving averages and strong support at $136. The company demonstrates robust fundamentals with a 38.37% net income margin, consistent earnings beats, and strategic AI partnerships enhancing its cybersecurity offerings. Recent news highlights ESG reporting and cloud security expansions.
Outlook remains positive with a consensus price target of $148.73, though risks include insider sales and legal investigations. The stock offers growth potential from AI integration but faces competitive and regulatory headwinds that warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
